Hepcidin levels in chronic hemodialysis patients: A critical evaluation

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 5, 2014, Pages 613-619

  Valenti, Luca ^a   Messa, Piergiorgio ^b   Pelusi, Serena ^a   Campostrini, Natascia ^c   Girelli, Domenico ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

anemia; chronic hemodialysis; chronic kidney disease; hepcidin; iron

Indexed keywords

HEPCIDIN; IRON;

ANEMIA; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE COURSE; ERYTHROPOIESIS; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE DETERMINATION; HUMAN; IRON STORAGE; KIDNEY DISEASE; MACROPHAGE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; PATHOLOGY; RENAL REPLACEMENT THERAPY;

ANEMIA; HEPCIDINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 84898999044     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0769     Document Type: Article

References (40)

1. Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010;24:39-47.
2. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63-72. (Pubitemid 29031210)
3. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 2004;43:671-84. (Pubitemid 38401882)
4. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-33.
5. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3. (Pubitemid 40007660)
6. Ganz T. Macrophages and systemic iron homeostasis. J Innate Immun 2012;4:446-53.
7. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab 2008;8:1-3. (Pubitemid 351859233)
8. Canavesi E, Valenti L. Modulation of iron metabolism and hepcidin release by HFE mutations in chronic hemodialysis patients: pathophysiological and therapeutic implications. In: Penido MG, editor. Hemodialysis: Intech Open Access Publisher, 2011:139-72.
9. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6.
10. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381-7. (Pubitemid 44232041)
11. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010;5:1010-4.
12. Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol 2010;2010:329646.
13. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythro-poietin therapy. Eur J Clin Invest 2009;39:883-90.
14. Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, et al. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1331-7.
15. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-81.
16. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 2010;25:848-53.
17. Tessitore N, Girelli D, Campostrini N, Bedogna V, Solero P, Castagna A, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010;25:3996-4002.
18. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89:87-93.
19. Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009;122:226-9.
20. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31: 534-40.
21. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23:1631-4.
22. Shoji S, Inaba M, Tomosugi N, Okuno S, Ichii M, Yamakawa T, et al. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013;90:237-44.
23. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 2012;122:4635-44.
24. Pelusi S, Girelli D, Rametta R, Campostrini N, Alfieri C, Traglia M, et al. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol 2013;14:48.
25. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010;73:527-36.
26. Kroot J, Laarakkers C, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al. Immunochemical and mass spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570-9.
27. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292-7.
28. Campostrini N, Traglia M, Martinelli N, Corbella M, Cocca M, Manna D, et al. Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study. J Proteomics 2012;76 Spec No.:28-35.
29. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328-33. (Pubitemid 43053559)
30. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 2008;3:e2706.
31. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, Sala C, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011;48:629-34.
32. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:e218-25.
33. Peters HP, Rumjon A, Bansal SS, Laarakkers CM, van den Brand JA, Sarafidis P, et al. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant 2012;27:3923-9.
34. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7:e39783.
35. Stefansson BV, Abramson M, Nilsson U, Haraldsson B. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2012;2:55-65.
36. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis- stimulating agents: a MRI study. Am J Med 2012;125:991-9 e1.
37. Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, Davis T, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:299-307.
38. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011;31:683-90.
39. Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, et al. Hepcidin as well as TNF-{alpha} are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-7.
40. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2012 Nov 19. [Epub ahead of print].